FDA Accepts Supplemental Application for ABREVA by Haleon
The FDA has accepted a supplemental application for ABREVA, a cold sore treatment containing docosanol.
Therapeutic Area
Therapeutic area intelligence for Cold Sores with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.